Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 17, 2019
May 15, 2020
1a0bec17-eee8-4dda-9b43-4ca488355d7f
Related Documents
Benefit-Risk Assessment for New Drug and Biological Products
Guidance DocumentOctober 17, 2023Center for Drug Evaluation and Research
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Guidance DocumentJuly 27, 2022Center for Drug Evaluation and Research
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry: Guidance for Industry
Guidance DocumentNovember 9, 2020Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox